Drug Type HSA fusion protein |
Synonyms insulinotropic hormone secretion peptide fusion protein(Wuxi Hebang Biotechnology Co. Ltd.), HB 1085, HB-1085 + [3] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 1 | China | 06 Dec 2019 |






